Article Text

Download PDFPDF
E05 Mutation-related apparent myelin, not axon density, drives white matter pathology in premanifest huntington’s disease: evidence from in vivo ultra-strong gradient MRI
  1. Chiara Casella1,2,
  2. Maxime Chamberland1,3,
  3. Pedro Luque Laguna1,
  4. Greg D Parker1,
  5. Anne Rosser4,5,
  6. Elizabeth Coulthard6,
  7. Hugh Rickards7,8,
  8. Derek K Jones1,
  9. Claudia Metzler-Baddeley1
  1. 1Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, UK
  2. 2Department of Perinatal Imaging and Health, School of Biomedical Engineering and Imaging Sciences, King‘s College London, London, UK
  3. 3Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, the Netherlands
  4. 4Department of Neurology and Psychological Medicine, Hayden Ellis Building, Cardiff, UK
  5. 5School of Biosciences, Cardiff University, Cardiff, UK
  6. 6Bristol Medical School, University of Bristol, Bristol, UK
  7. 7Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK
  8. 8Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK

Abstract

Background White matter (WM) impairments precede striatal atrophy and motor symptoms in Huntington’s disease (HD) but their aetiology remains unknown.

Aims We exploited ultra-strong gradient MRI to disentangle the contribution of changes in axon microstructure versus changes in myelin to WM pathology in HD.

Methods We assessed apparent myelin [with the magnetization transfer ratio (MTR)], and axon density [with the restricted volume fraction (FR) from the Composite Hindered and Restricted Model of Diffusion (CHARMED)] in premanifest HD patients and age- and sex-matched controls. Group differences in diffusion tensor MRI measures were also assessed. We investigated region-specific changes across the corpus callosum (CC) with tractometry and brain-wise WM microstructure abnormalities with tract-based cluster analysis (TBCA). Behavioural measures were included to explore disease-associated brain-function relationships.

Results We detected lower apparent myelin in the posterior CC of patients (tractometry: p = 0.0343; TBCA: p = 0.030), and higher apparent myelin in the anterior CC (tractometry: p = 0.016). A positive association between apparent myelin and mutation size in patients (all p-values < 0.01) suggested a direct link between myelin alterations and disease mutation. Higher FR in the cortico-spinal tract (CST) (TBCA: p = 0.03) was detected in patients, demonstrating that WM changes in premanifest HD extend beyond the CC. FR in the CST was associated with MTR in the posterior CC (p = 0.033) and a trend was present for a positive association with cognitive performance (p = 0.057), suggesting compensation to myelin loss.

Conclusions We provide novel in vivo evidence for myelin-based WM alterations as an early feature of human HD. Critical pathogenic events were present in mutation carriers prior to clinical onset, emphasising the importance of understanding the mechanisms underlying early WM abnormalities for the discovery of new therapeutic approaches.

  • premanifest huntington’s disease
  • white matter microstructure
  • myelin
  • axon
  • MRI

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.